182 results about "Vitiligo" patented technology

The invention provides application of UBR5 in preparation of drugs for treating pigmented skin diseases, and further the pigmented skin diseases comprise various types of pigmented nevus (mainly congenital pigmented nevus and megalous with the risk of malignant transformation). Various pigmented spots (mainly chloasma, freckles, Taitian nevus, post-inflammation hyperpigmentation and the like) and hypopigmentation / depigmentation spots (mainly leucoderma, post-inflammation hypopigmentation and the like). Experimental results show that UBR5 is highly expressed in disease tissues such as pigmented nevus. The UBR5 expression level and the melanogenesis ability are in significant positive correlation, targeted knockout / knockdown of UBR5 in melanocytes can significantly inhibit the expression level of melanogenesis related genes such as MITF, TRP1, TRP2, TYR and other proteins, the melanin content of melanocytes and tyrosinase activity, vice versa, and the melanogenesis ability of melanocytes after overexpression of UBR5 is significantly increased.

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

The invention relates to application of VBIT-4 or pharmaceutically acceptable salt thereof in preparation of drugs for preventing or treating vitiligo and complications thereof. A large number of modern pharmacological scientific researches and in-vivo pharmacodynamic tests prove that VBIT-4 has a treatment effect on a leucoderma mouse model and inhibits synthesis of inflammatory factors and chemotactic factors in a leucoderma mouse skin lesion area. The mechanism of the invention is that VBIT-4 inhibits the expression of inflammatory factors and chemotactic factors in skin tissues so as to treat leucoderma, compared with the existing treatment means, VBIT-4 can promote the compound color of pigments in a skin lesion region on the back of a leucoderma mouse, has no obvious toxicity, and reduces the expression level of inflammatory factors (IL-1beta, IL-6 and IFN-alpha) and chemotactic factors (CXCL9 and CXCL10). In conclusion, the VBIT-4 is clear in action mechanism, remarkable in effect and free of obvious side effects, and has remarkable advantages and progress compared with existing drugs.

The application provides a tyrosinase-based transdermal delivery system for treating vitiligo, which is a core-shell structure, the core is tyrosinase, and the shell is a polymer shell layer. The application coats a polymer protective layer on the surface of the tyrosinase through in-situ polymerization reaction on the double bond of the tyrosinase, can effectively protect the activity of the tyrosinase and promote the transdermal delivery of the tyrosinase, and can control the targeted delivery of the tyrosinase nanogel to melanocytes in the deep part of the skin and hair follicle by adjusting the polymerization conditions of the polymer shell, so as to promote the in-situ synthesis of melanin. The transdermal delivery system of the application can also load active small molecules with anti-inflammatory function in the center of the tyrosinase, and the small molecules are released after being targeted and delivered to the inflammation area of vitiligo along with the tyrosinase nanogel, so as to relieve inflammation and protect melanocytes from damage.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition liniment for treating vitiligo and a preparation method of the traditional Chinese medicine composition liniment. The concentrated liquid medicine, 3-OH phlorizin and vegetable oil are mixed, and the liniment is obtained; and bottling and storing. Various Chinese herbal medicine components are prepared into the liniment, the liniment aims at improving skin conditions and promoting pigment recovery in an external application mode, the extracted Chinese herbal medicine components and 3-OH phlorizin are added into the vegetable oil, the adding amount and proportion are controlled, the dispersion uniformity and effect of the final liniment are ensured, parameters are determined according to actual working procedure conditions, and the liniment has the advantages of being simple in structure, convenient to use and high in practicability. According to the liniment preparation device, production requirements of different batches are flexibly met, so that stability and intelligence of batch production are achieved, intelligence of the production process is achieved by automatically monitoring and adjusting opening and closing of the feeding valve, the liniment preparation process is optimized, product quality and stability are improved, and production intelligence and adaptability are enhanced.

The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

The invention discloses a method for determining chemical components in a medicine for treating vitiligo and a method for establishing a fingerprint spectrum. Comprising the following steps: S1, preparing a to-be-detected solution and a reference substance solution: grinding Bailing tablets, dissolving the Bailing tablets in a solvent, and extracting to prepare the to-be-detected solution; dissolving a paeoniflorin reference substance in a solvent to prepare a reference substance solution; wherein the extraction solvent is a methanol-water mixed solution; s2, respectively obtaining chromatograms of the to-be-detected solution and the reference substance solution under the same detection conditions by adopting ultra-high performance liquid chromatography, and carrying out qualitative analysis and / or quantitative analysis on chemical components in the chromatograms of the to-be-detected solution; wherein the detection conditions are as follows: the wavelength of a detector is 201 + / -2nm; the elution conditions are as follows: acetonitrile is used as a phase A, water is used as a phase B, and elution is performed through a gradient elution procedure. According to the method, the chemical components in the medicine for treating the leucoderma can be accurately determined, so that the establishment of the fingerprint spectrum database of the medicine for treating the leucoderma can be better realized.

1. Name of the product of this design: Ultraviolet light therapy pen (CN‑308P II). 2. Purpose of the product of this design: UV irradiation treatment for skin diseases such as vitiligo, psoriasis, pityriasis rosea, eczema, etc. 3. Key points of the design of this product: The combination of shape and pattern. 4. The picture or photo that best illustrates the key points of the design: Stereoscopic picture.

The formula comprises the following components in parts by weight: 5 parts of scorpio, 10 parts of gastrodia elata, 20 parts of stiff silkworm, 30 parts of cicada slough, 15 parts of radix sophorae flavescentis, 12 parts of divaricate saposhnikovia root, 12 parts of schizonepeta, 15 parts of notopterygium root, 6 parts of asarum, 10 parts of radix angelicae, 20 parts of ligusticum wallichii, 15 parts of angelica sinensis, 10 parts of radix paeoniae alba, 15 parts of ginseng, 10 parts of bighead atractylodes rhizome, 20 parts of fructus aurantii, 20 parts of platycodon grandiflorum, 10 parts of coptis chinensis, 12 parts of golden cypress, 6 parts of rheum officinale, 6 parts of mirabilite, 6 parts of ephedra, 15 parts of gypsum, 30 parts of talc, 20 parts of spina gleditsiae, 10 parts of climbing gold, 15 parts of gardenia The medicine is prepared from 40 parts of radix rehmanniae recen, 20 parts of rhizoma coptidis, 20 parts of radix scutellariae, 20 parts of fructus forsythiae, 18 parts of rhizoma cimicifugae, 25 parts of platycodon grandiflorum, 10 parts of liquorice, 12 parts of scorpio, 20 parts of radix rehmanniae, 30 parts of fructus ziziphi spinosae, 18 parts of wood, 16 parts of rumex japonicus, 12 parts of barberry and The formula for treating vitiligo, purpura and purpura is prepared from pure traditional Chinese medicines, is small in side effect and low in price, can radically treat vitiligo, purpura and purpura, and has very high practical value and popularization value.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

The invention provides application of psoralen A in preparation of a medicine for treating vitiligo and a system for treating vitiligo, and belongs to the technical field of medicines. According to the application of the psoralen A in preparing the medicine for treating the vitiligo, the medicine for treating the vitiligo is prepared by adopting the flavone compound psoralen A, the toxicity is low, and the medicine has a good curative effect on the vitiligo in combination with ultraviolet light (such as UVA).

The invention discloses a preparation method of drug-loaded membrane protein bionic vesicles based on a microfluidic technology and application of the drug-loaded membrane protein bionic vesicles to targeted melanocyte delivery drugs, and belongs to the technical field of pharmaceutical preparations. The method is easy and convenient to operate, assembly of the phospholipid bilayer and insertion of the membrane protein are accurately controlled through the laminar focusing technology, and the stable and efficient drug-loaded membrane protein bionic vesicle is formed. The drug-loaded membrane protein bionic vesicles can effectively target melanocytes, promote the uptake of the vesicles, significantly improve the accumulation of drugs in the melanocytes, and enhance the treatment effect on melanocyte related diseases (such as hyperpigmentation, melanoma, vitiligo and the like). Meanwhile, the drug-loaded bionic vesicles constructed by the invention have relatively low keratinocyte uptake rate, drug uptake of non-targeted tissues is effectively reduced, and side effects of drugs are reduced, so that the drug-loaded membrane protein bionic vesicle system constructed by the invention has great prospects in the aspect of treating melanocyte related diseases.

The utility model provides a vitiligo novel target ultraviolet light therapeutic instrument, relates to skin treatment equipment technical field, including base, console, adjusting tube and phototherapy head, the console is installed on the base, the adjusting tube connects the console and the phototherapy head, the phototherapy head is provided with ultraviolet light source inside, and the ultraviolet light source is connected with the base. The front end of the phototherapy head is provided with an adjustable light shield, so that the problems that the irradiation range of the phototherapy head cannot be adjusted, a vitiligo disease area is not targeted, and surrounding normal skin can be irradiated in the use process of an existing ultraviolet light therapeutic apparatus can be solved; and the problems that the irradiation position and angle are not easy to fix when a traditional handheld phototherapy head is used for irradiation, and the phototherapy head is directly contacted with the skin due to mistaken touch are solved.

The invention relates to a method for rapidly preparing vernonia anthelmintica dealicin from vernonia anthelmintica dealicin, which comprises the following steps: carrying out ultrasonic extraction by using ethanol, enriching by using macroporous resin to obtain a vernonia anthelmintica dealicin extract, and carrying out extraction and pilot plant test preparative liquid chromatography separation to obtain a high-purity vernonia anthelmintica dealicin compound. The results of subsequent researches show that the vernonia anthelmintica dealicin can significantly inhibit the secretion of the chemotactic factor, and the inhibition rate of 1mol / L of vernonia anthelmintica dealicin on the release level of the chemotactic factor CXCL10 reaches 75.83%. The vernonia anthelmintica macrobrachin reduces the recruitment of self-reactive T cells to the skin by blocking a CXCL10-mediated inflammation signal channel, so that melanocytes are protected, and pigment regeneration is promoted. Therefore, the vernonia anthelmintica macrobrachin inhibits the secretion of the chemotactic factor CXCL10 in a targeted manner, can be used as a potential effective monomeric compound in the development of vitiligo medicines for research, and is expected to become a new strategy for treating vitiligo.

The invention relates to application of a CGRP receptor inhibitor in preparation of a medicine for relieving or treating leucoderma. According to the application disclosed by the invention, the condition that the CGRP receptor is associated with occurrence and development of the vitiligo is determined for the first time, and the CGRP receptor inhibitor can be used for effectively relieving or treating the vitiligo. The CGRP receptor inhibitor, especially Ubrogeant or Rimegeant, can be used for realizing pharmacological regulation and control on the vitiligo. The invention further provides a method for screening candidate drugs acting on the CGRP receptor so as to relieve or treat leucoderma.

A method of producing a rapamycin-containing composition for treating skin disease, which comprises the steps of dissolving rapamycin in an ethanol-containing solvent, adding a gelling and / or thickening agent to the resulting rapamycin-containing solution, and adjusting the pH of the resulting rapamycin-containing composition to 5.5 to 6.1 with triethanolamine or tris(hydroxymethyl)aminomethane (TRIS) is provided. A method of inhibiting degradation of rapamycin in a rapamycin-containing composition for treating skin diseases, wherein the method comprises the step of adjusting the pH of the composition to 5.5 to 6.1 with triethanolamine or tris(hydroxymethyl)aminomethane is also provided. A rapamycin-containing composition for treating skin diseases comprising (i) rapamycin, (ii) carboxylic acid-containing aqueous polymer, and (iii) at least one pH adjuster selected from triethanolamine and tri(hydroxymethyl)aminomethane, having a pH of 5.5 to 6.1 is also provided. The carboxylic acid-containing polymer may be carboxy vinyl polymer (carbomer), carboxymethyl cellulose or carboxyethyl cellulose. The skin disease may be dermatitis, contact dermatitis, psoriasis, atopic dermatitis, seborrheic dermatitis, nummular eczema, vitiligo, keloids, autosensitised dermatitis, stasis dermatitis, sebaceous deficiency eczema, skin tumours of tuberous sclerosis, and skin tumours of Recklinghausen’s disease. Preferred topical gels comprise rapamycin, carboxy vinyl polymer (carbomer), ethanol, water and either triethanolamine or tris(hydroxymethyl)aminomethane.

The invention discloses observation of the curative effect of AKBA gel combined with narrow-spectrum UVB irradiation in treatment of leucoderma. The invention creatively discovers that the combined use of AKBA and phototherapy has a remarkable and better treatment effect on leucoderma for the first time, provides an effective drug combination strategy for treatment of leucoderma, and has a good clinical application prospect and important conversion significance in the technical field of research and development of leucoderma treatment drugs.

Methods of treating autoimmune skin diseases and disorders are provided. The methods typically include administrating to a subject with an autoimmune skin disease or disorder an effective amount of a hypoxia-inducible factor-1 (HIF-1) inhibitor. In preferred embodiments, the autoimmune disease is mediated at least in-part by T cells, particularly skin-infiltrating T cells. In some embodiments, the subject has cutaneous lupus (e.g., discoid cutaneous lupus, subacute cutaneous lupus, acute cutaneous lupus), pemphigus, pemphigoid, epidermolysis bullosa acquisita, vitiligo, lichen planus, lichen sclerosus, dermatomyositis, alopecia areata, or Sjögren's syndrome. HIF-1 inhibitors and pharmaceutical compositions including the same for use in the disclosed methods are also provided. The HIF-1 inhibitor can be, for example, a small molecule, functional nucleic acid, or inhibitory polypeptide or protein. The pharmaceutical composition can be formulated to suitable for the type and mode of administration, e.g., systemically or locally to skin effected by the autoimmune disease.

The composition is prepared from the following components in parts by weight: 150-250 parts of radix angelicae, 200-350 parts of peach kernels, 20-60 parts of honeysuckle flowers, 10-30 parts of red roses with double petals, 20-40 parts of dried ginger and 10-30 parts of Chinese dates, meridian tropism, property, flavor and function analysis is performed on a meridian prescription, medicinal and edible homology replacement is performed, and under the control of clear quality indexes, the composition is obtained through extraction, and the composition is used for treating leucoderma. Activity tests prove that the traditional Chinese medicine composition has the effect of assisting in improving vitiligo. The invention further discloses a preparation process and an analysis method of the composition for assisting in improving vitiligo.

The invention relates to the technical field of Vibrio harveyi detection, and specifically to a method for rapid detection of Vibrio harveyi, comprising stabilization and taking out; the beneficial effects are as follows: a plurality of placement frames are arranged on the top of a base, the placement frames comprising a boiling water bath, a thermal cycle position and an observation position, and a culture dish can be quickly moved to a corresponding position, thereby speeding up the operation speed and not causing the spillage of reagents; the culture dish is placed on the surface of a placement plate, and a force-bearing plate moves with the force-bearing plate, so that the placement plate is retracted into a fixed frame, and a spring is held on the movable plate, so that the holding teeth are held on the surface of a pressing plate, and the pressing plate is held on the surface of the force-bearing plate, so that the placement plate is fixed and the culture dish is stabilized.

The invention discloses application of an ATP (adenosine triphosphate) citrate lyase (ACLY) inhibitor in preparation of a medicine for treating leucoderma, and belongs to the technical field of preparation of medicines for treating leucoderma. Through targeted inhibition of ACLY activity or specific knockout of ACLY in CD8 + T cells, abnormal activation of ACLY and secretion of killing effector molecules (Granzyme B, IFN-gamma, Perforin and the like) are inhibited, and infiltration of the CD8 + T cells to skin lesion parts is reduced, so that melanocytes are protected from immune injury, and the progress of vitiligo is blocked. The application is based on the abnormally high expression of ACLY in CD8 + T cells of vitiligo patients and the close association with disease activity, and a brand new targeted treatment thought and a medicine research and development direction are provided for vitiligo.

1. Name of the product in this design: Ultraviolet Phototherapy Device (308 nm). 2. Intended use of this design: Treatment of psoriasis and vitiligo. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention discloses application of rifudine in preparation of a preparation for promoting cell melanin synthesis, and belongs to the technical field of special drugs. The invention provides a new application of rifudine, which can promote synthesis and secretion of melanin and expression of TYR, TRP-1 and TRP-2, provides a new functional component for enhancing synthesis of melanin in vivo and preparing products for treating vitiligo and the like, and has a wide application prospect in the fields of pharmaceutical preparations, cosmetics, care products, beauty products and the like.

The invention discloses a traditional Chinese medicine for treating leucoderma and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. Comprising medicine for oral administration, astragalus membranaceus, codonopsis pilosula, bighead atractylodes rhizome, rhizoma smilacis glabrae, Chinese yam, fructus psoraleae, angelica sinensis, buffalo horn shreds, dogwood, salvia miltiorrhiza, red paeony root, safflower carthamus, ligusticum wallichii, peach kernel, polygonum multiflorum, eclipta alba, white mulberry root-bark, divaricate saposhnikovia root, radix bupleuri, scutellaria baicalensis, curcuma aromatica, fingered citron, rhizoma cyperi, felwort, parched white peony root, tribulus terrestris, gardenia, radix angelicae and rhizoma typhonii. The external immersion liquid comprises fructus psoraleae, radix angelicae, cortex dictamni, radix polygoni multiflori, borax, rhizoma typhonii, semen cuscutae, flos carthami and white spirit. Through oral administration for regulating qi and blood, tonifying liver and kidney, dredging meridians and collaterals and consolidating root, external application for dredging local parts and promoting pigment, internal and external synergism and simultaneous treatment of both symptoms and root causes, the traditional Chinese medicine is especially suitable for middle-aged and elderly patients with qi and blood deficiency, deficiency of liver and kidney and qi stagnation and blood stasis type leucoderma.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The application discloses a chitosan-glycine-copper chelate and a preparation method and application thereof in treating leukoplakia and vitiligo. In the preparation, chitosan is first placed in an acid aqueous phase system, and is fully dissolved and forms a uniform transparent or translucent solution under stirring; then glycine is added, and the chitosan and the glycine are fully mixed under stirring to build an organic ligand environment containing multiple coordination groups; subsequently, a copper source is introduced to perform a chemical reaction, and finally the chitosan-glycine-copper chelate is obtained. The chitosan-glycine-copper chelate shows a strong promoting activity completely different from all other substances (including simple mixtures of components thereof), the chelate can continuously and significantly activate tyrosinase activity, and promote the formation of melanin, so that the purpose of treating leukoplakia and vitiligo is achieved.

The application discloses a compound morinda officinalis color-increasing liniment for treating vitiligo and a preparation method thereof, and particularly relates to the technical field of traditional Chinese medicine preparations, wherein the liniment is prepared from morinda officinalis, spilanthes acmella, giant knotweed, caesalpinia sappan, psoralea corylifolia, radix angelicae dahuricae and rhizoma smilacis glabrae as raw medicinal materials. The preparation method comprises the following steps: dynamic reflux extraction, percolation extraction, macroporous adsorption resin purification and preparation molding. Through the classification extraction and purification process, the photosensitive active ingredients are retained, and the photo-toxic impurities are effectively removed, so that the photo-toxicity is completely negative. The pharmacodynamic test shows that the liniment has a significant curative effect on vitiligo. The safety test shows that the liniment has no skin irritation and no allergenicity, and has excellent light safety. The quality research shows that the quality of the liniment is stable and controllable. The liniment has definite curative effect, high safety and stable quality, and has a good clinical application prospect.

The invention discloses an application of a substance for detecting a marker group. The application comprises one or more of the following applications: A1) an application in preparation of a product for predicting sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma, and A2) an application in preparation of a product for predicting sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma; a2) is applied to preparation of a product for screening sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma; a3) in preparation of a product for evaluating sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma; the marker group is composed of CCL5, FGL1, EZR and GAPDH (glyceraldehyde-phosphate dehydrogenase). The invention screens and verifies the plasma and urine biomarker group capable of predicting the sensitivity of treating leucoderma by combining baricitinib with narrow-spectrum medium-wave ultraviolet rays of a subject through ELISA (Enzyme-Linked Immunosorbent Assay), and the plasma and urine biomarker group provided by the invention has higher prediction accuracy, sensitivity and specificity; the individualized treatment of vitiligo can be improved, and good clinical application and popularization prospects are achieved.

The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.